An H3N2 influenza mRNA vaccine targeting the tandem HA and NA proteins and its preparation method
By designing an H3N2 influenza mRNA vaccine with HA and NA proteins tandem, the shortcomings of existing vaccines in terms of production efficiency, cost, and broad-spectrum protection have been addressed, achieving highly effective immune protection against the H3N2 influenza virus, making it suitable for responding to influenza outbreaks.
Patent Information
- Application Number
- CN202510976598.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-16
- Publication Date
- 2026-05-26
- Estimated Expiration
- 2045-07-16
AI Technical Summary
Existing influenza vaccines have shortcomings in terms of production efficiency, cost, immunization efficacy, and applicable population, making it difficult to achieve broad-spectrum protection, especially in dealing with immune evasion by variant strains of the H3N2 influenza virus.
A mRNA vaccine for H3N2 influenza targeting the tandem amino acids HA and NA was designed. The conserved amino acid sequences of HA and NA were linked by a flexible peptide, the codons were optimized, a plasmid was constructed, transcribed into mRNA, and then prepared into lipid nanoparticles (LNPs) to improve the immune protection effect.
It achieves broad-spectrum protection against the H3N2 influenza virus, reduces production costs, enhances the effectiveness of the vaccine throughout the immunization cycle, and provides an effective response to influenza outbreaks.